drugset
drugset / Trial / NCT04695041

A Healthy Volunteer Study of PBI-4050

NCT04695041 ↗

Phase 1 Completed 65 enrolled Liminal BioSciences Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to investigate the study drug PBI-4050 to determine the safety, tolerability and concentration profile in the blood when the drug is given to healthy volunteers as multiple doses and different dosing regimens over a period of 14 days.

Timeline

Start
2020-12-09
Primary completion
2021-10-05
Completion
2021-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SETOGEPRAM Small molecule 800 mg —
Subject SETOGEPRAM Small molecule 1000 mg —
Subject SETOGEPRAM Small molecule 1200 mg —

Indications

No indication recorded.